Source link : https://newshealth.biz/health-news/bispecific-antibody-improves-pfs-in-egfr-mutated-lung-cancer/
The HARMONi trial showed ivonescimab plus chemotherapy reduced disease progression risk by 48% in patients with EGFR-mutated NSCLC after TKI failure. Medscape Medical News Source link : https://www.medscape.com/viewarticle/bispecific-antibody-improves-pfs-egfr-mutated-lung-cancer-2025a1000nyr?src=rss Author : Publish date : 2025-09-10 18:55:00 Copyright for syndicated content belongs to the linked Source.
The post Bispecific Antibody Improves PFS in EGFR-Mutated Lung Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-10 18:55:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8